Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections.

Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H.

Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1311-22. doi: 10.1007/s10096-014-2070-6. Epub 2014 Feb 15.

PMID:
24532009
2.

Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.

Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A.

Int J Antimicrob Agents. 2014 Apr;43(4):378-82. doi: 10.1016/j.ijantimicag.2014.01.016. Epub 2014 Feb 14.

PMID:
24613422
3.

Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.

Balkan II, Batirel A, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H.

Indian J Pharmacol. 2015 Jan-Feb;47(1):95-100. doi: 10.4103/0253-7613.150383.

4.

Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.

Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, Acikgoz ZC.

J Infect Dev Ctries. 2015 May 18;9(5):476-85. doi: 10.3855/jidc.6195.

5.

Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.

Kalin G, Alp E, Akin A, Coskun R, Doganay M.

Infection. 2014 Feb;42(1):37-42. doi: 10.1007/s15010-013-0495-y. Epub 2013 Jul 5.

PMID:
23828559
6.

Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.

Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC.

Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.

PMID:
25793437
7.

Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.

Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R.

Clin Infect Dis. 2013 Aug;57(3):349-58. doi: 10.1093/cid/cit253. Epub 2013 Apr 24.

8.

Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.

Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y.

Clin Infect Dis. 2015 May 1;60(9):1295-303. doi: 10.1093/cid/civ048. Epub 2015 Jan 28.

9.

In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.

Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.

J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.

PMID:
24265334
10.

Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.

Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A.

J Med Assoc Thai. 2010 Feb;93(2):161-71.

PMID:
20301995
11.

Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.

Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, Espejo-Gutiérrez de Tena E, Artero-González ML, Corcia-Palomo Y, Bautista-Paloma J.

Chemotherapy. 2013;59(3):225-31. doi: 10.1159/000356004. Epub 2013 Dec 13.

PMID:
24356297
12.

Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.

Vandepitte WP, Berge J, Andersson R.

J Med Assoc Thai. 2014 Nov;97 Suppl 11:S129-39.

PMID:
25509707
13.

Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.

Garnacho-Montero J, Amaya-Villar R, Ferrándiz-Millón C, Díaz-Martín A, López-Sánchez JM, Gutiérrez-Pizarraya A.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):769-77. doi: 10.1586/14787210.2015.1032254. Epub 2015 Apr 12. Review.

PMID:
25865094
14.

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.

J Antimicrob Chemother. 2007 Aug;60(2):317-22. Epub 2007 May 31.

15.
16.

Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Lin HS, Lee MH, Cheng CW, Hsu PC, Leu HS, Huang CT, Ye JJ.

Infect Dis (Lond). 2015 Jun;47(6):370-8. doi: 10.3109/00365548.2014.995129. Epub 2015 Mar 6.

PMID:
25746600
17.

Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.

Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH.

Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8.

18.

Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.

Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J.

Antimicrob Agents Chemother. 2010 Mar;54(3):1165-72. doi: 10.1128/AAC.00367-09. Epub 2010 Jan 4.

19.

Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes.

Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, Ahmed H, Pogue JM, Zhao JJ, Kaye KS.

Antimicrob Agents Chemother. 2013 Dec;57(12):6270-5. doi: 10.1128/AAC.01520-13. Epub 2013 Oct 7.

20.

In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.

Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L.

J Antibiot (Tokyo). 2014 Sep;67(9):677-80. doi: 10.1038/ja.2014.99. Epub 2014 Aug 6.

PMID:
25095805
Items per page

Supplemental Content

Write to the Help Desk